Always fun at the Kardium summer BBQ. Great to hang out with our team and their families.
Über uns
Kardium is developing a revolutionary medical device for the diagnosis and treatment of atrial fibrillation. .
- Website
-
http://www.kardium.com
External link for Kardium Inc.
- Industrie
- Herstellung medizinischer Geräte
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Burnaby, BC
- Typ
- In Privatbesitz
- Gegründet
- 2007
Standorte
-
Primäre
Wegbeschreibung erhalten
8518 Glenlyon Pkwy
155
Burnaby, BC V5J 0B6, CA
Employees at Kardium Inc.
Aktualisierungen
-
Thank you TSX Trust for the congratulations at the Toronto Stock Exchange on our $104M financing!
-
-
Kardium Inc. reposted this
Thanks Christopher Woods, MD PhD for sharing your positive thoughts on our clinical data. We are also looking forward to sharing the exciting results of the PULSAR study.
Exciting clinical results from the PULSE-EU study of the Globe System presented today at #HRS2024 84.2 % freedom from Atrial Arrhythmia 0% Major adverse events* 23 minutes average to isolate all pulmonary veins 1.2 average applications per vein #Globe #AFib #epeeps * Major adverse events: Stroke, thromboembolism, pericardial effusion, esophageal fistula, phrenic nerve paralysis, PV stenosis, major vascular complications
-
Kardium Inc. reposted this
Here is our CEO Kevin sharing details about our device. We are on a path to delivering the best treatment for afib! Come and join us!
In this episode of the DeviceTalks Weekly podcast, Kevin Chaplin, CEO of Kardium Inc., a Vancouver-based #electrophysiology device company, shares details of the company’s Globe® Pulsed Field Mapping and Ablation System. With $100 million in new capital, the company is poised to open a new front in the pulsed-field ablation battle. Thank you to Freudenberg Medical for sponsoring this episode. LISTEN HERE: https://lnkd.in/eZkNUPMx #PulsedFieldAblation #ElectrophysiologyDevice #CardiacAblation #CardiacDevice #Cardiac #PFA Tom Salemi
-
-
Nasdaq congratulates Kardium Inc. on closing our recent financing round. That's pretty cool!
-
-
Here is our CEO Kevin sharing details about our device. We are on a path to delivering the best treatment for afib! Come and join us!
In this episode of the DeviceTalks Weekly podcast, Kevin Chaplin, CEO of Kardium Inc., a Vancouver-based #electrophysiology device company, shares details of the company’s Globe® Pulsed Field Mapping and Ablation System. With $100 million in new capital, the company is poised to open a new front in the pulsed-field ablation battle. Thank you to Freudenberg Medical for sponsoring this episode. LISTEN HERE: https://lnkd.in/eZkNUPMx #PulsedFieldAblation #ElectrophysiologyDevice #CardiacAblation #CardiacDevice #Cardiac #PFA Tom Salemi
-
-
Kardium Inc. reposted this
Congratulations to Kardium Inc.! On May 31, they successfully raised USD $104 million in a financing round led by Fidelity Management And Research Company, alongside T. Rowe Price Associates, Inc., T. Rowe Price Investment Management, Inc., and new investor Durable Capital Partners LP. This significant investment will accelerate Kardium's initiatives, including completing the PULSAR clinical study, securing regulatory approvals, expanding manufacturing capabilities, and establishing a strong clinical and commercial team for the Globe System launch. Our team was honored to support Kardium Inc. throughout this transformative journey. Learn more: https://bit.ly/3KOmT6i #ClientSuccess #MedicalInnovation #AtrialFibrillation #HealthcareInnovation #LegalExcellence #Fasken #KardiumInc
-
-
Exciting news at Kardium Inc.! We've secured funding that will allow us to pursue regulatory approval and commercial launch of the Globe System! We look forward to bringing the best treatment for atrial fibrillation to the world! Thanks to the teams at Fidelity Investments, T. Rowe Price, Durable Capital Partners LP for your investment and supporting our mission at Kardium Inc. https://lnkd.in/g53gKKge
-
Thanks Christopher Woods, MD PhD for sharing your positive thoughts on our clinical data. We are also looking forward to sharing the exciting results of the PULSAR study.
Exciting clinical results from the PULSE-EU study of the Globe System presented today at #HRS2024 84.2 % freedom from Atrial Arrhythmia 0% Major adverse events* 23 minutes average to isolate all pulmonary veins 1.2 average applications per vein #Globe #AFib #epeeps * Major adverse events: Stroke, thromboembolism, pericardial effusion, esophageal fistula, phrenic nerve paralysis, PV stenosis, major vascular complications
-
Congratulations Kardium Inc. team on these fantastic results!
Exciting clinical data from the Globe System was recently presented at the HRS conference and also published in the HRS journal. https://lnkd.in/g-2v7Wqn
Kardium announces positive 1-year outcomes for PULSE-EU trial with the Globe® System, showing promise for improving the treatment of atrial fibrillation
businesswire.com